Similar to this, lebrikizumab is an IgG4k monoclonal antibody that selectively binds to IL-13, blocking the heterodimerization of IL-13Rα1/IL-4Rα and the ensuing signaling, which ultimately stops the proliferation of AD [67,68]. This evidence concerns the gene IL13RA1 and Alzheimer disease.